136 related articles for article (PubMed ID: 20605507)
1. Fracture risk in early postmenopausal women assessed using FRAX.
Trémollieres F; Cochet T; Cohade C; Pouillès JM; Ribot C
Joint Bone Spine; 2010 Jul; 77(4):345-8. PubMed ID: 20605507
[TBL] [Abstract][Full Text] [Related]
2. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.
Kanis JA; McCloskey EV; Johansson H; Strom O; Borgstrom F; Oden A;
Osteoporos Int; 2008 Oct; 19(10):1395-408. PubMed ID: 18751937
[TBL] [Abstract][Full Text] [Related]
3. Fracture risk assessment tool (FRAX) and for the diagnosis of osteoporosis in Japanese middle-aged and elderly women: Chiba bone survey.
Oka R; Ohira M; Suzuki S; Yoshida T; Koide H; Tanaka T; Tatsuno I
Endocr J; 2018 Feb; 65(2):193-202. PubMed ID: 29151451
[TBL] [Abstract][Full Text] [Related]
4. Determination of an applicable FRAX model in Korean women.
Lee DY; Lim SJ; Moon YW; Min YK; Choi D; Yoon BK; Park YS
J Korean Med Sci; 2010 Nov; 25(11):1657-60. PubMed ID: 21060757
[TBL] [Abstract][Full Text] [Related]
5. Ten-year absolute fracture risk and hip bone strength in Canadian women with systemic lupus erythematosus.
Lee JJ; Aghdassi E; Cheung AM; Morrison S; Cymet A; Peeva V; Neville C; Hewitt S; DaCosta D; Pineau C; Pope J; Fortin PR
J Rheumatol; 2012 Jul; 39(7):1378-84. PubMed ID: 22660811
[TBL] [Abstract][Full Text] [Related]
6. 2018 update of French recommendations on the management of postmenopausal osteoporosis.
Briot K; Roux C; Thomas T; Blain H; Buchon D; Chapurlat R; Debiais F; Feron JM; Gauvain JB; Guggenbuhl P; Legrand E; Lehr-Drylewicz AM; Lespessailles E; Tremollieres F; Weryha G; Cortet B
Joint Bone Spine; 2018 Oct; 85(5):519-530. PubMed ID: 29654947
[TBL] [Abstract][Full Text] [Related]
7. Is lower income associated with an increased likelihood of qualification for treatment for osteoporosis in Canadian women?
Brennan SL; Leslie WD; Lix LM
Osteoporos Int; 2014 Jan; 25(1):273-9. PubMed ID: 23907573
[TBL] [Abstract][Full Text] [Related]
8. Use of FRAX®-based fracture risk assessments to identify patients who will benefit from osteoporosis therapy.
Silverman SL; Komm BS; Mirkin S
Maturitas; 2014 Nov; 79(3):241-7. PubMed ID: 25124532
[TBL] [Abstract][Full Text] [Related]
9. The utility of dual-energy X-ray absorptiometry, calcaneal quantitative ultrasound, and fracture risk indices (FRAX® and Osteoporosis Risk Assessment Instrument) for the identification of women with distal forearm or hip fractures: A pilot study.
Esmaeilzadeh S; Cesme F; Oral A; Yaliman A; Sindel D
Endocr Res; 2016 Aug; 41(3):248-60. PubMed ID: 26864472
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®.
Kaufman JM; Palacios S; Silverman S; Sutradhar S; Chines A
Osteoporos Int; 2013 Oct; 24(10):2561-9. PubMed ID: 23595562
[TBL] [Abstract][Full Text] [Related]
11. Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool.
Trémollieres FA; Pouillès JM; Drewniak N; Laparra J; Ribot CA; Dargent-Molina P
J Bone Miner Res; 2010 May; 25(5):1002-9. PubMed ID: 20200927
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of pharmacotherapy in postmenopausal osteoporosis: a longitudinal observational study.
Pluskiewicz W; Adamczyk P; Franek E; Sewerynek E; Wichrowska H; Napiórkowska L; Stuss M; Rozwandowicz A; Drozdzowska B
Endokrynol Pol; 2019; 70(6):473-477. PubMed ID: 31909456
[TBL] [Abstract][Full Text] [Related]
13. Osteodensitometry in healthy postmenopausal women.
Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
[TBL] [Abstract][Full Text] [Related]
14. Fracture Risk Assessment Tool (FRAX®) Results Calculated With and Without Bone Mineral Density Values for the Evaluation of Fracture Risk in Postmenopausal Women With Osteopenia.
Imerci A; Yalın Kılınç C; Aydogan NH; Karalezli MN; Savran A
J Clin Densitom; 2018; 21(4):464-471. PubMed ID: 28781230
[TBL] [Abstract][Full Text] [Related]
15. Direct comparison of eight national FRAX® tools for fracture prediction and treatment qualification in Canadian women.
Leslie WD; Brennan SL; Lix LM; Johansson H; Oden A; McCloskey E; Kanis JA
Arch Osteoporos; 2013; 8():145. PubMed ID: 23929269
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of densitometry and fracture risk assessment tool FRAX in making therapeutic decisions in osteoporosis--a study on female patients of university of medical sciences endocrinology outpatient clinic].
Ignaszak-Szczepaniak M; Dytfeld J; Michalak M; Gowin E; Horst-Sikorska W
Ginekol Pol; 2009 Jun; 80(6):424-31. PubMed ID: 19642598
[TBL] [Abstract][Full Text] [Related]
17. Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.
Siris ES; Baim S; Nattiv A
Postgrad Med; 2010 Jan; 122(1):82-90. PubMed ID: 20107292
[TBL] [Abstract][Full Text] [Related]
18. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
Kanis JA; Johansson H; Oden A; McCloskey EV
Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
[TBL] [Abstract][Full Text] [Related]
19. Correlation between osteoporotic fracture risk in Brazilian postmenopausal women calculated using the FRAX with and without the inclusion of bone densitometry data.
Bastos-Silva Y; Aguiar LB; Pinto-Neto AM; Baccaro LF; Costa-Paiva L
Arch Osteoporos; 2016; 11():16. PubMed ID: 27067597
[TBL] [Abstract][Full Text] [Related]
20. Application of the World Health Organization Fracture Risk Assessment Tool to predict need for dual-energy X-ray absorptiometry scanning in postmenopausal women.
Chao AS; Chen FP; Lin YC; Huang TS; Fan CM; Yu YW
Taiwan J Obstet Gynecol; 2015 Dec; 54(6):722-5. PubMed ID: 26700992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
